The drug that Neurocrine Biosciences licensed from Idorsia for $50 million has flunked a second Phase II study, failing to help pediatric patients with a rare type of epilepsy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,